- Report
- August 2025
- 150 Pages
Global
From €3401EUR$3,850USD£2,980GBP
- Report
- August 2025
- 150 Pages
Global
From €3401EUR$3,850USD£2,980GBP
- Report
- July 2025
- 150 Pages
Global
From €3401EUR$3,850USD£2,980GBP
€4284EUR$4,850USD£3,754GBP
- Report
- July 2025
- 150 Pages
Global
From €3401EUR$3,850USD£2,980GBP
€4284EUR$4,850USD£3,754GBP
- Report
- April 2025
- 150 Pages
Global
From €3401EUR$3,850USD£2,980GBP
€4284EUR$4,850USD£3,754GBP
- Report
- February 2025
- 150 Pages
Global
From €3401EUR$3,850USD£2,980GBP
€4284EUR$4,850USD£3,754GBP
- Report
- June 2025
- 95 Pages
Global
From €4284EUR$4,850USD£3,754GBP
- Report
- May 2025
- 120 Pages
Global
From €3642EUR$4,123USD£3,191GBP
€4284EUR$4,850USD£3,754GBP
- Report
- May 2025
- 138 Pages
Global
From €3642EUR$4,123USD£3,191GBP
€4284EUR$4,850USD£3,754GBP
- Report
- May 2025
- 140 Pages
Global
From €3642EUR$4,123USD£3,191GBP
€4284EUR$4,850USD£3,754GBP
- Report
- April 2025
- 210 Pages
Global
From €3975EUR$4,500USD£3,483GBP
- Report
- March 2025
- 197 Pages
Global
From €4373EUR$4,950USD£3,831GBP
- Report
- May 2025
- 125 Pages
United States
From €2871EUR$3,250USD£2,515GBP
- Report
- June 2025
- 100 Pages
United States
From €3489EUR$3,950USD£3,057GBP
- Report
- March 2025
- 120 Pages
North America
From €3534EUR$4,000USD£3,096GBP
- Report
- May 2025
- 84 Pages
United States
From €3092EUR$3,500USD£2,709GBP
- Report
- May 2025
- 145 Pages
United States
From €2208EUR$2,500USD£1,935GBP
- Report
- November 2025
- 110 Pages
North America
From €2440EUR$2,763USD£2,138GBP
€2871EUR$3,250USD£2,515GBP
- Report
- November 2025
- 140 Pages
United States
From €1915EUR$2,168USD£1,678GBP
€2253EUR$2,550USD£1,974GBP
- Report
- March 2025
- 99 Pages
Europe
From €3048EUR$3,450USD£2,670GBP

Age-related Macular Degeneration (AMD) is a degenerative eye condition that affects the macula, the part of the eye responsible for central vision. It is the leading cause of vision loss in people over the age of 50. AMD is a major concern for the optical industry, as it can lead to severe vision impairment and blindness.
Optical companies are developing treatments and technologies to help diagnose and manage AMD. These include optical coherence tomography (OCT) imaging, which can detect early signs of AMD, and anti-VEGF drugs, which can slow the progression of the disease. Additionally, companies are developing new lenses and other optical devices to help improve vision in those with AMD.
Companies in the AMD market include Novartis, Regeneron, Allergan, Genentech, and Roche. Show Less Read more